« Home

Home » Chemistry » Patrick: An Introduction to Medicinal Chemistry 4e » Student resources » Hyperlinked bibliography » Chapter 21

Patrick: An Introduction to Medicinal Chemistry 4e

Chapter 21

Further reading

Atkins, J. H., and Gershell, L. J. (2002) Selective anticancer drugs. Nature Reviews Drug Discovery, 1, 491-492 [DOI: 10.1038/nrd842] [PubMed: 12120255].

Elsayed, Y. A., and Sausville, E. A. (2001) Selected novel anticancer treatments targeting cell signalling proteins. The Oncologist 6, 517-537 [DOI: 10.1634/theoncologist.6-6-517] [PubMed: 11743214].

Featherstone, J., and Griffiths, S. (2002) Drugs that target angiogenesis. Nature Reviews Drug Discovery, 1, 413-414 [DOI: 10.1038/nrd824] [PubMed: 12119742].

Goldberg, A. L., Elledge, S. J., and Harper, J. W. (2001) The cellular chamber of doom. Scientific American, January, 68-73 [PubMed: 11132426].

Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70 [DOI: 10.1016/S0092-8674(00)81683-9] [PubMed: 10647931].

Jain, R. K., and Carmeliet, P. F. (2001) Vessels of death. Scientific American, December, 27-33 (angiogenesis).

Jordan, V. C. (2003) Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2, 205-213 [DOI: 10.1038/nrd1031] [PubMed: 12612646].

Neidle, S., and Parkinson, G. (2002) Telomere maintenance as a target for anticancer drug discovery. Nature Reviews Drug Discovery, 1, 383-393 [DOI: 10.1038/nrd793] [PubMed: 12120414].

Ojima, I., Vite, G. D., and Altmann, K.-H. (eds.). (2001) Anticancer agents. ACS Symposium Series 796, American Chemical Society, Washington, DC.

Opalinska, J. B., and Gewirtz, A. M. (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nature Reviews Drug Discovery, 1, 503-514 [DOI: 10.1038/nrd837] [PubMed: 12120257].

Pecorino, L. (2008) Molecular biology of cancer: mechanisms, targets and therapeutics, 2nd edition, Oxford University Press.

Reed, J. C. (2002) Apoptosis-based therapies. Nature Reviews Drug Discovery, 1, 111-121 [DOI: 10.1038/nrd726] [PubMed: 12120092].

Szakacs, G., et al. (2006) Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5, 219-234 [DOI: 10.1038/nrd1984] [PubMed: 16518375].

Thurston, D. E. (2006) Chemistry and Pharmacology of Anticancer Drugs. CRC Press.

Wayt Gibbs, W. (2003) Untangling the roots of cancer. Scientific American, July, 48-57.

Weissman, K. (2003) Life and cell death. Chemistry in Britain, August, 19-22.

Zhang, J. Y. (2002) Apoptosis-based anticancer drugs. Nature Reviews Drug Discovery, 1, 101-102 [DOI: 10.1038/nrd742] [PubMed: 12120090].

Topoisomerase poisons

Fang, L., et al. (2006) Discovery of a daunorubicin analogue that exhibits potent antitumour activity and overcomes P-gp-meditated drug resistance. Journal of Medicinal Chemistry, 49, 932-941 [DOI: 10.1021/jm050800q] [PubMed: 16451059].

Fortune, J. M., and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs. Progress in Nucleic Acid Research and mole bio, 64, 221-253 [DOI: 10.1016/S0079-6603(00)64006-0].

Pommier, Y., et al. (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochimica et Biophysica Acta, 1400, 83-106 [PubMed: 9748515].

Platinum-based agents

Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 7, 573-584 [DOI: 10.1038/nrc2167].

Wang, D., and Lippard, S. J. (2005) Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery, 4, 307-320 [DOI: 10.1038/nrd1691] [PubMed: 15789122].

Agents acting on tubulin and microtubules

Farina, V. (ed.). (1995) The chemistry and pharmacology of taxol and its derivatives. Elsevier, Amsterdam.

Hormonal therapy

Brzozowski, A. M., et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-758 [DOI: 10.1038/39645] [PubMed: 9338790].

Jordan, C. (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Journal of Medicinal Chemistry, 46, 1081-1111 [DOI: 10.1021/jm020450x] [PubMed: 12646017].

Photodynamic therapy

Lane, N. (2003) New light on medicine. Scientific American, January, 26-33.

Farnesyltransferase inhibitors

Bell, I. M. (2004) Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? Journal of Medicinal Chemistry, 47, 1-10 [DOI: 10.1021/jm0305467].

Protein kinase inhibitors

Atkins, M., Jones, C. A., and Kirkpatrick, (2006). Sunitinib maleate. Nature Reviews Drug Discovery, 5, 279-280 [DOI: 10.1038/nrd2012] [PubMed: 16628834].

Barker, A. J., et al. (2001) Studies leading to the identification of ZD 1839 (Iressa). Bioorganic and Medical. Chemistry Letters, 11, 1911-1914 [DOI: 10.1016/S0960-894X(01)00344-4].

Capdeville, R., et al. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery, 1, 493-502 [DOI: 10.1038/nrd839] [PubMed: 12120256].

Collins, I., and Workman, P. (2006) Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets. Current Signal Transduction. Therapy, 1, 13-23.

Dancey, J., and Sausville, E. A. (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nature Reviews Drug Discovery, 2, 296-313 [DOI: 10.1038/nrd1066] [PubMed: 12669029].

Janin, Y. L. (2005) Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? Journal of Medicinal Chemistry, 48, 7503-7512 [DOI: 10.1021/jm050759r] [PubMed: 16302791].

Moy, B., Kirkpatrick, P., and Goss, P. (2007) Lapatinib. Nature Reviews Drug Discovery, 6, 431-432 [DOI: 10.1038/nrd2332] [PubMed: 17633789].

Quintas-Cardama, A., Kantarjian, H., and Cortes, J. (2007) Flying under the radar: the new wave of BCR-ABL inhibitors. Nature Reviews Drug Discovery, 6, 1-15 [DOI: 10.1038/nrd2324].

Rini, B., Kar, S., and Kirkpatrick, P. (2007) Temsirolimus. Nature Reviews Drug Discovery, 6, 599-600 [DOI: 10.1038/nrd2382].

Zaiac, M. (2002) Taking aim at cancer. Chemistry in Britain, November, 44-46.

Miscellaneous enzyme inhibitors and other agents

Bartlett, J. B., Dredge, K., and Dalgleish, A. G. (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews Cancer, 4, 314-322 [DOI: 10.1038/nrc1323].

Jarvis, L. M. (2007) Living on the edge. Chemical and Enginering. News, Febr 26, 15-23.

Johnstone, R. W. (2002) Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 1, 287-299 [DOI: 10.1038/nrd772] [PubMed: 12120280].

McLaughlin, F., Finn, P., and La Thangue, N. B. (2003) The cell cycle, chromatin and cancer. Drug Discovery Today, 8, 793-802 [DOI: 10.1016/S1359-6446(03)02792-2].

Sanchez-Serrano, (2006). Success in translational research: lessons from the development of bortezomib. Nature Reviews Drug Discovery, 5, 107-114 [DOI: 10.1038/nrd1959] [PubMed: 16518378].

Whittaker, M., et al. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chemical Reviews, 99, 2735-2776 [DOI: 10.1021/cr9804543] [PubMed: 11749499].

Yoo, C, B., and Jones, P. A. (2006) Epigenetic therapy of cancer: past, present and future (2006). Nature Reviews Drug Discovery, 5, 37-50 [DOI: 10.1038/nrd1930] [PubMed: 16485345].

Antibodies and gene therapy

Dubowchik, G. M., and Walker, M. A. (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacology and Therapeutics, 83, 67-123 [DOI: 10.1016/S0163-7258(99)00018-2] [PubMed: 10511457].

Ezzell, C. (2001) Magic bullets fly again. Scientific American, October, 28-35 (antibodies).

Schrama, D., Reisfeld, R. A., and Becker, J. C. (2006) Antibody targeted drugs as cancer therapeutics. Nature Reviews Drug Discovery, 5, 147-159 [DOI: 10.1038/nrd1957] [PubMed: 16424916].

Senter, P. D., and Springer, C. J. (2001) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Advanced Drug Delivery Reviews, 53, 247-264 [DOI: 10.1016/S0169-409X(01)00206-X] [PubMed: 11744170].